GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease.

Humans Diabetes Mellitus, Type 2 / drug therapy Glucagon-Like Peptide-1 Receptor / agonists Male Female Middle Aged Aged Acute Kidney Injury / mortality Hypoglycemic Agents / therapeutic use Cardio-Renal Syndrome / drug therapy Cardiovascular Diseases / mortality Treatment Outcome Glucagon-Like Peptide-1 Receptor Agonists

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
13 Jul 2024
Historique:
received: 03 02 2024
accepted: 03 07 2024
medline: 14 7 2024
pubmed: 14 7 2024
entrez: 13 7 2024
Statut: epublish

Résumé

Previous studies have explored the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing cardiovascular events in type 2 diabetes. Here we show that GLP-1 RAs are associated with lower risks of mortality, major cardiovascular events (MACEs), and major adverse kidney events (MAKEs) in type 2 diabetes patients with acute kidney disease (AKD). Utilizing global data from the TriNetX database (2002/09/01-2022/12/01) and propensity score matching, we compare 7511 GLP-1 RAs users to non-users among 165,860 AKD patients. The most common causes of AKI are sepsis (55.2%) and cardiorenal syndrome (34.2%). After a median follow-up of 2.3 years, GLP-1 RAs users exhibit reduced risks of mortality (adjusted hazard ratio [aHR]: 0.57), MACEs (aHR: 0.88), and MAKEs (aHR: 0.73). External validation in a multicenter dataset of 1245 type 2 diabetes patients with AKD supports the favorable outcomes. These results emphasize the potential of GLP-1 RAs in individualized treatment for this population.

Identifiants

DOI: 10.1038/s41467-024-50199-y PMID: 39003287
pubmed: 39003287
doi: 10.1038/s41467-024-50199-y
pii: 10.1038/s41467-024-50199-y
doi:

Substances chimiques

Glucagon-Like Peptide-1 Receptor 0
Hypoglycemic Agents 0
Glucagon-Like Peptide-1 Receptor Agonists 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5912

Subventions

Organisme : Ministry of Science and Technology, Taiwan (Ministry of Science and Technology of Taiwan)
ID : 109-2321-B-182-001
Organisme : Ministry of Health and Welfare, Taiwan | Health Promotion Administration, Ministry of Health and Welfare (Health Promotion Administration of the Taiwan Ministry of Health and Welfare)
ID : MOHW112-TDU-B-212-144005
Organisme : Chang Gung Medical Foundation
ID : CMRPG-2K0091

Informations de copyright

© 2024. The Author(s).

Références

Haw, J. S. et al. Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern. Med. 177, 1808–1817 (2017).
pubmed: 29114778 pmcid: 5820728 doi: 10.1001/jamainternmed.2017.6040
Zheng, Y., Ley, S. H. & Hu, F. B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat. Rev. Endocrinol. 14, 88 (2018).
pubmed: 29219149 doi: 10.1038/nrendo.2017.151
Fang, W.-C. et al. Thermal Perception Abnormalities Can Predict Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients. Kidney Blood Press. Res. 45, 926–938 (2020).
pubmed: 33053551 doi: 10.1159/000510479
Hsu, R. K., McCulloch, C. E., Dudley, R. A., Lo, L. J. & Hsu, C.-Y. Temporal changes in incidence of dialysis-requiring AKI. J. Am. Soc. Nephrol. 24, 37–42 (2013).
pubmed: 23222124 doi: 10.1681/ASN.2012080800
Pan, H. C. et al. Recovery Dynamics and Prognosis After Dialysis for Acute Kidney Injury. JAMA Netw. Open 7, e240351 (2024).
pubmed: 38457183 pmcid: 10924241 doi: 10.1001/jamanetworkopen.2024.0351
Su, C.-C. et al. Outcomes associated with acute kidney disease: A systematic review and meta-analysis. EClinicalMedicine 55, 101760 (2023).
pubmed: 36531983 doi: 10.1016/j.eclinm.2022.101760
Patschan, D. & Müller, G. Acute kidney injury in diabetes mellitus. Int. J. Nephrol. 2016(2016).
Alicic, R. Z., Rooney, M. T. & Tuttle, K. R. Diabetic kidney disease: challenges, progress, and possibilities. Clin. J. Am. Soc. Nephrol. 12, 2032–2045 (2017).
pubmed: 28522654 pmcid: 5718284 doi: 10.2215/CJN.11491116
Kaballo, M. A., Elsayed, M. E. & Stack, A. G. Linking acute kidney injury to chronic kidney disease: the missing links. J. Nephrol. 30, 461–475 (2017).
pubmed: 27928735 doi: 10.1007/s40620-016-0359-5
Hapca, S. et al. The relationship between AKI and CKD in patients with type 2 diabetes: an observational cohort study. J. Am. Soc. Nephrol. 32, 138–150 (2021).
pubmed: 32948670 doi: 10.1681/ASN.2020030323
Ndumele, C. E. et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation 148, 1606–1635 (2023).
pubmed: 37807924 doi: 10.1161/CIR.0000000000001184
Ndumele, C. E. et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation 148, 1636–1664 (2023).
pubmed: 37807920 doi: 10.1161/CIR.0000000000001186
Müller, T. D. et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 30, 72–130 (2019).
pubmed: 31767182 pmcid: 6812410 doi: 10.1016/j.molmet.2019.09.010
Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).
pubmed: 27633186 doi: 10.1056/NEJMoa1607141
Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).
pubmed: 27295427 pmcid: 4985288 doi: 10.1056/NEJMoa1603827
Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228–1239 (2017).
pubmed: 28910237 pmcid: 9792409 doi: 10.1056/NEJMoa1612917
Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121–130 (2019).
pubmed: 31189511 doi: 10.1016/S0140-6736(19)31149-3
Shaman, A. M. et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145, 575–585 (2022).
pubmed: 34903039 doi: 10.1161/CIRCULATIONAHA.121.055459
Filippatos, T. D. & Elisaf, M. S. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J. Diabetes 4, 190–201 (2013).
pubmed: 24147203 pmcid: 3797884 doi: 10.4239/wjd.v4.i5.190
Muskiet, M. H. A. et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat. Rev. Nephrol. 13, 605–628 (2017).
pubmed: 28869249 doi: 10.1038/nrneph.2017.123
Caruso, P., Maiorino, M. I., Bellastella, G., Esposito, K. & Giugliano, D. Pleiotropic effects of GLP-1 receptor agonists on peripheral artery disease: Is there any hope? Diabetes Metab. Res Rev. 39, e3627 (2023).
pubmed: 36812501 doi: 10.1002/dmrr.3627
Tommerdahl, K. L., Kendrick, J. & Bjornstad, P. The role of glucagon-like peptide 1 (GLP-1) receptor agonists in the prevention and treatment of diabetic kidney disease: insights from the AMPLITUDE-O trial. Clin. J. Am. Soc. Nephrol. 17, 905–907 (2022).
pubmed: 35396319 pmcid: 9269664 doi: 10.2215/CJN.00020122
Schuetz, P., Castro, P. & Shapiro, N. I. Diabetes and sepsis: preclinical findings and clinical relevance. Diabetes Care 34, 771–778 (2011).
pubmed: 21357364 pmcid: 3041224 doi: 10.2337/dc10-1185
Shah, F. A. et al. Therapeutic Effects of Endogenous Incretin Hormones and Exogenous Incretin-Based Medications in Sepsis. J. Clin. Endocrinol. Metab. 104, 5274–5284 (2019).
pubmed: 31216011 pmcid: 6763279 doi: 10.1210/jc.2019-00296
Chen, J.-J. et al. Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease. JAMA Netw. Open 5, e221169–e221169 (2022).
pubmed: 35254430 pmcid: 8902651 doi: 10.1001/jamanetworkopen.2022.1169
Gerstein, H. C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N. Engl. J. Med. 385, 896–907 (2021).
pubmed: 34215025 doi: 10.1056/NEJMoa2108269
Pfeffer, M. A. et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N. Engl. J. Med 373, 2247–2257 (2015).
pubmed: 26630143 doi: 10.1056/NEJMoa1509225
Gragnano, F., De Sio, V. & Calabrò, P. FLOW trial stopped early due to evidence of renal protection with semaglutide. Eur. Heart J. Cardiovasc Pharmacother. 10, 7–9 (2024).
pubmed: 37934595 doi: 10.1093/ehjcvp/pvad080
Tonneijck, L. et al. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. J. Am. Soc. Nephrol. 28, 1023–1039 (2017).
pubmed: 28143897 pmcid: 5373460 doi: 10.1681/ASN.2016060666
Drucker, D. J. The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metab. 24, 15–30 (2016).
pubmed: 27345422 doi: 10.1016/j.cmet.2016.06.009
Vitale, M., Haxhi, J., Cirrito, T. & Pugliese, G. Renal protection with glucagon-like peptide-1 receptor agonists. Curr. Opin. Pharm. 54, 91–101 (2020).
doi: 10.1016/j.coph.2020.08.018
Muskiet, M. H. A. et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 6, 859–869 (2018).
pubmed: 30292589 doi: 10.1016/S2213-8587(18)30268-7
Husain, M. et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N. Engl. J. Med 381, 841–851 (2019).
pubmed: 31185157 doi: 10.1056/NEJMoa1901118
Goodwill, A. G. et al. Cardiovascular and hemodynamic effects of glucagon-like peptide-1. Rev. Endocr. Metab. Disord. 15, 209–217 (2014).
pubmed: 24881624 pmcid: 4119853 doi: 10.1007/s11154-014-9290-z
Zhou, X. et al. Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats. Cardiovasc Diabetol. 14, 29 (2015).
pubmed: 25888997 pmcid: 4476171 doi: 10.1186/s12933-015-0194-3
Pandey, S., Mangmool, S. & Parichatikanond, W. Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective. Pharmaceuticals (Basel) 16 (2023).
Nikolaidis, L. A. et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109, 962–965 (2004).
pubmed: 14981009 doi: 10.1161/01.CIR.0000120505.91348.58
Chen, Y.-T. et al. Acute kidney disease and acute kidney injury biomarkers in coronary care unit patients. BMC Nephrol. 21, 1–11 (2020).
doi: 10.1186/s12882-020-01872-z
Wang, H. et al. Patient outcomes following AKI and AKD: a population-based cohort study. BMC Med. 20, 1–17 (2022).
doi: 10.1186/s12916-022-02428-8
Chen, J.-J. et al. Acute kidney disease after acute decompensated heart failure. Kidney Int. Rep. 7, 526–536 (2022).
pubmed: 35257065 pmcid: 8897687 doi: 10.1016/j.ekir.2021.12.033
Yang, C. Y., Chen, Y. R., Ou, H. T. & Kuo, S. Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. Cardiovasc Diabetol. 20, 21 (2021).
pubmed: 33468131 pmcid: 7816439 doi: 10.1186/s12933-020-01211-4
Wang, W., Wang, C.-Y., Wang, S.-I. & Wei, J. C.-C. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine 53, 101619 (2022).
pubmed: 35971425 pmcid: 9366236 doi: 10.1016/j.eclinm.2022.101619
Pan, H.-C. et al. Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease. JAMA Netw. Open 7, e2350050–e2350050 (2024).
pubmed: 38170522 pmcid: 10765268 doi: 10.1001/jamanetworkopen.2023.50050
Topaloglu, U. & Palchuk, M. B. Using a Federated Network of Real-World Data to Optimize Clinical Trials Operations. JCO Clin. Cancer Inf. 2, 1–10 (2018).
Wu, V. C., Chen, J. Y., Lin, Y. H., Wang, C. Y. & Lai, C. C. Assessing the cardiovascular events and clinical outcomes of COVID-19 on patients with primary aldosteronism. J. Microbiol Immunol. Infect. 56, 1158–1168 (2023).
pubmed: 37827953 doi: 10.1016/j.jmii.2023.09.005
Yang, S. Y. et al. Nomenclature and diagnostic criteria for acute kidney injury - 2020 consensus of the Taiwan AKI-task force. J. Formos. Med Assoc. 121, 749–765 (2022).
pubmed: 34446340 doi: 10.1016/j.jfma.2021.08.005
Hsieh, C. C. et al. Nephrologist follow-up care for the acute kidney injury-chronic kidney disease continuum and clinical outcomes: A systematic review and meta-analysis. J. Chin. Med Assoc. 87, 280–286 (2024).
pubmed: 38289278 doi: 10.1097/JCMA.0000000000001052
Guo, X. H. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide. Curr. Med Res Opin. 32, 61–76 (2016).
pubmed: 26439329 doi: 10.1185/03007995.2015.1103214
Morieri, M. L., Avogaro, A. & Fadini, G. P. Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice. Diabetes Metab. Syndr. Obes. 13, 4221–4234 (2020).
pubmed: 33204129 pmcid: 7665457 doi: 10.2147/DMSO.S216054
Andrade, C. Mean Difference, Standardized Mean Difference (SMD), and Their Use in Meta-Analysis: As Simple as It Gets. J. Clin. Psychiatry 81 (2020).
Guo, J. C.-L. et al. Associations between using Chinese herbal medicine and long-term outcome among pre-dialysis diabetic nephropathy patients: a retrospective population-based cohort study. Front. Pharmacol. 12, 616522 (2021).
pubmed: 33679399 pmcid: 7930622 doi: 10.3389/fphar.2021.616522
Mathur, M. B., Ding, P., Riddell, C. A. & VanderWeele, T. J. Web Site and R Package for Computing E-values. Epidemiology 29, e45–e47 (2018).
pubmed: 29912013 pmcid: 6066405 doi: 10.1097/EDE.0000000000000864
VanderWeele, T. J. & Ding, P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann. Intern Med 167, 268–274 (2017).
pubmed: 28693043 doi: 10.7326/M16-2607
Pan, H. C. et al. Predialysis serum lactate levels could predict dialysis withdrawal in Type 1 cardiorenal syndrome patients. EClinicalMedicine 44, 101232 (2022).
pubmed: 35059613 pmcid: 8760464 doi: 10.1016/j.eclinm.2021.101232
Shao, S. C. et al. The Chang Gung Research Database—a multi‐institutional electronic medical records database for real‐world epidemiological studies in Taiwan. Pharmacoepidemiol. Drug Saf. 28, 593–600 (2019).
pubmed: 30648314 doi: 10.1002/pds.4713

Auteurs

Heng-Chih Pan (HC)

Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chang Gung University College of Medicine, Taoyuan, Taiwan.
Division of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
Community Medicine Research Center, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
Kidney Research Center and Department of Nephrology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Jui-Yi Chen (JY)

Division of Nephrology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Department of Health and Nutrition, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.
ORCID: 0000-0003-1376-7780

Hsing-Yu Chen (HY)

Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Division of Chinese Internal Medicine, Center for Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.

Fang-Yu Yeh (FY)

Division of Nephrology, Primary Aldosteronism Center of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Chiao-Yin Sun (CY)

Division of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
Kidney Research Center and Department of Nephrology, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Thomas Tao-Min Huang (TT)

Division of Nephrology, Primary Aldosteronism Center of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
NSARF (National Taiwan University Hospital Study Group of ARF), and CAKS (Taiwan Consortium for Acute Kidney Injury and Renal Diseases), Taipei, Taiwan.

Vin-Cent Wu (VC)

Division of Nephrology, Primary Aldosteronism Center of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. q91421028@ntu.edu.tw.
NSARF (National Taiwan University Hospital Study Group of ARF), and CAKS (Taiwan Consortium for Acute Kidney Injury and Renal Diseases), Taipei, Taiwan. q91421028@ntu.edu.tw.
ORCID: 0000-0001-7935-0991

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › GLP-1 receptor agonists' impact on...
questionsmedicales.fr › Maladies endocriniennes › Diabète › Diabète de type 2 › GLP-1 receptor agonists' impact on...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur hormone gastrointestinale › Récepteurs des peptides similaires au glucagon › Récepteur du peptide-1 similaire au glucagon › GLP-1 receptor agonists' impact on...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › GLP-1 receptor agonists' impact on...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › GLP-1 receptor agonists' impact on...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Maladies du rein › Insuffisance rénale › Atteinte rénale aigüe › GLP-1 receptor agonists' impact on...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hypoglycémiants › GLP-1 receptor agonists' impact on...
questionsmedicales.fr › Maladies cardiovasculaires › Cardiopathies › Défaillance cardiaque › Syndrome cardiorénal › GLP-1 receptor agonists' impact on...
questionsmedicales.fr › Maladies cardiovasculaires › GLP-1 receptor agonists' impact on...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › GLP-1 receptor agonists' impact on...